Phase II trial of immunogenicity and reactogenicity of V 710 for the prevention of Staphylococcus aureus infections in patients with end-stage renal disease undergoing haemodyalysis

Trial Profile

Phase II trial of immunogenicity and reactogenicity of V 710 for the prevention of Staphylococcus aureus infections in patients with end-stage renal disease undergoing haemodyalysis

Not stated
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2010

At a glance

  • Drugs V-710 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 23 Nov 2010 New trial record
    • 18 Nov 2010 Initial top-line results have been reported in an Intercell AG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top